Nathaniel Wang

Dr. Nathaniel Wang is the Chief Executive Officer at Replicate Bioscience and cofounder of the company. He has over 15 years of leadership experience in immunology and drug development. He is a pioneer in synthetic, self-replicating RNA technologies and their delivery, including the development of the Replicate srRNA platform. He is also a recognized expert in the fields of immuno-oncology and infectious disease.

Prior to Replicate Bioscience, Dr. Wang was head of the RNA Medicines business unit at Synthetic Genomics, where he developed a self-replicating RNA platform asset. This asset and business unit was sold to Janssen in 2019. At Janssen, he setup a drug discovery and CMC framework and led teams developing compounds in multiple therapeutic spaces using the acquired technologies.

Dr. Wang has played critical roles in both biotech and pharma settings on cross functional teams involving R&D, clinical, business, commercial, legal, and regulatory with strategic oversight of preclinical and clinical assets through commercialization.

Dr. Wang is an inventor on multiple patents for applications of synthetic biology and use of novel technologies for vaccines and therapeutics. He received a Ph.D. in Immunology from The Scripps Research Institute. Prior to this, he earned a B.A. in Molecular Immunology from University of California, at Berkeley.